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ABSTRACT Monitoring asthma in children in clinical practice is primarily performed by reviewing
disease activity (daytime and night-time symptoms, use of reliever medication, exacerbations requiring
frequent use of reliever medication and urgent visits to the healthcare professional) and the impact of the
disease on children’s daily activities, including sports and play, in a clinical interview. In such an interview,
most task force members also discuss adherence to maintenance therapy and the patients’ (and parents’)
views and beliefs on the goals of treatment and the amount of treatment required to achieve those goals.
Composite asthma control and quality of life measures, although potentially useful in research, have
limited value in clinical practice because they have a short recall window and do not cover the entire
spectrum of asthma control. Telemonitoring of children with asthma cannot replace face-to-face follow-up
and monitoring because there is no evidence that it is associated with improved health outcomes.
@ERSpublications
To monitor asthma control in children interviewing the child and parents is preferred over
composite control scores http://ow.ly/JbqnR
Introduction
The ultimate goal of asthma treatment is to achieve and maintain clinical control and reduce future risks
to the patient. To reach this goal in children with asthma, ongoing monitoring is essential. Recently, a
European Respiratory Society Task Force on Monitoring Asthma in Childhood was published [1].
Although asthma guidelines place a strong emphasis on monitoring asthma control, there is no gold
standard for asthma control. The Global Initiative for Asthma (GINA) proposes to define levels of asthma
control based on clinical manifestations, forced expiratory volume in 1 s (FEV1) and expected future risk,
and classifies patients as well-controlled, partly controlled or uncontrolled [2]. Similarly, the British Thoracic
Society (BTS) guidelines for asthma control are based on clinical manifestations and FEV1 [3]. The National
Asthma Education and Prevention Programme (NAEPP) defines control as “the degree to which the
manifestations of asthma are minimized by therapeutic interventions and the goals of therapy are met” [4].
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The aims of this review are to provide an in-depth discussion of the evidence for the usefulness of
different tools available to monitor symptoms, exacerbations of asthma and quality of life (QoL) in
children with asthma. In particular, we will discuss monitoring in view of appropriateness in different age
groups. In this issue of the European Respiratory Review, three other articles will address general
considerations on monitoring asthma in children, lung function and inflammatory markers, and
management-related issues [5–7].
After establishing the diagnosis and agreeing on a treatment plan, children with asthma need to be
followed up regularly to allow adequate provision of self-management education [8]. This usually takes at
least two educational and instructional sessions, in which children and parents are encouraged to express
concerns, questions and beliefs; in addition, inhalation techniques are taught and checked. Afterwards,
most task force members will review the patient at least twice a year to discuss the degree of asthma
control achieved and to evaluate whether maintenance treatment should be modified accordingly.
Monitoring symptoms
The key symptom of asthma is wheeze, caused by intrathoracic airway narrowing. This is usually
accompanied by shortness of breath, chest tightness and cough (table 1). For patients, the things they hate
most about their asthma, apart from having to take medication on a daily basis, are asthma attacks and the
limitations asthma imposes on their daily activities including sports and play [9].
Focusing on such patient-centred outcomes during follow-up may be enhanced by starting the
consultation by asking “What is useful for you to talk about today?”, instead of the usual “How has your
asthma been lately?” This can be followed by asking for specific symptoms (table 1). A review of reliever
medication use is recommended in asthma guidelines as an expression of asthma control. Most task force
members believe that a review of the much more important daily use of controller medication is of value
at every follow-up visit [10].
Symptoms (including limitation of activities such as exercise and play) and rescue medication use are
distinct domains in the clinical expression of asthma, independent from exacerbations, lung function and
inflammation [11]. Children vary considerably in the degree of airway narrowing they perceive as dyspnoea
of sufficient severity to prompt the use of reliever therapy [12]. It is likely that psychological factors,
including anxiety and depression, are related to the burden imposed on the patient by symptoms of asthma,
influencing their expression and perceived severity and impact [13]. Most asthma trials use diaries to
monitor symptoms, but the evidence does not support the use of such diaries in clinical practice [14]. In
addition, daily diaries in asthma have been shown to be unreliable, at least where peak flow is concerned
[15]. In summary, it is current practice to ask questions on symptoms listed in table 1, focusing on
patient-centred outcomes and medication use (both daily controller and reliever medication) at all visits.
Composite asthma control scores
Since the concept of asthma control has been introduced as a key feature in asthma guidelines, numerous
attempts have been made to capture it in a single numerical value.
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The full range of available paediatric composite asthma control scores has been reviewed elsewhere [16].
The two instruments with the most extensively reported validation are the (childhood) asthma control test,
ACT or C-ACT [17], and the asthma control questionnaire (ACQ) [18]. These are compared in table 2.
The ACT contains five items, with a recall window of 4 weeks. There is a separate version for children
aged 4–12 years (the C-ACT), which consists of four pictorial items that are scored by the children
themselves and three verbal items that are scored by the parents. One should be aware that children tend
to report their asthma control to be significantly lower than their parents [19, 20]. The ACQ contains six
items with a recall window of 1 week; this is supplemented by measurement of FEV1 as a percentage of
predicted (“the seventh question”) [18]. Two novel composite asthma control scores take exacerbations
into account: the Test for Respiratory and Asthma Control in Kids (TRACK) and the Composite Asthma
Severity Index (CASI) [21, 22]. This is important because most symptoms captured in composite asthma
control scores occur only, or most severely, during exacerbations, limiting the ability of asthma control
scores to capture variations in control over a brief recall window during which no exacerbations occur.
Poor asthma control, as measured by the ACT, C-ACT or ACQ, is associated with reduced lung function,
increased risk of exacerbations and elevated exhaled nitric oxide fraction, and is lower in children not
regularly using inhaled corticosteroid maintenance therapy [17, 18, 23–27]. Children with asthma and
allergic rhinitis have poorer asthma control and a higher risk of exacerbations than those without allergic
rhinitis [28, 29]. Children whose parents are concerned about the usefulness and side-effects of inhaled
corticosteroid therapy also have poorer asthma control [30], and this association is caused by poor
adherence to inhaled corticosteroids [31]. Follow-up studies have shown that changes in composite
measures of asthma control reflect changes in the overall clinical assessment of asthma control by
physicians, and the need to step up therapy [32]. No studies have assessed whether repeated structured
assessment of asthma control by composite control measures helps to improve asthma control during
long-term management and follow-up.
Although the concept of a composite asthma control score, which captures overall asthma control into a
single numerical value, is intuitively appealing, it is also a contradiction in terms, because it is universally
agreed that asthma control is a multidimensional construct [16]. Specifically, it has been recognised that
asthma control should encompass both current impairment and future risk of exacerbations [33, 34]. A recent
follow-up study in children showed that the degree of asthma control, as assessed by composite asthma
control measures, changes over time and shows variable concordance with the risk of exacerbations [35, 36].
Despite their relatively well-documented validation, the ACT and ACQ share three drawbacks which limit
their usefulness in clinical practice (table 3). Although the short recall window facilitates reliable
recollection of asthma events that have occurred recently, it fails to represent the variable nature of the
TABLE 2 Comparison of items in the asthma control test (ACT), childhood ACT and asthma
control questionnaire (ACQ)
Item ACT Childhood ACT ACQ
Nocturnal awakening + + (child and parent) +
Severity of nocturnal symptoms +
Limitation of daily activities + + (child) +
Shortness of breath + +
Wheeze + (parent) +
Use of rescue medication + +
Self-rated asthma control + + (child)
Cough + (child)
Daytime asthma symptoms + (parent)
+: indicates the item is incorporated into the score.
TABLE 3 Limitations of using composite measures of asthma control
Short recall window: 1–4 weeks
Do not take asthma exacerbations into account, except TRACK and CASI
Cover only part of the asthma control spectrum (table 1)
TRACK: Test for Respiratory and Asthma Control in Kids; CASI: Composite Asthma Severity Index.
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disease. Children may be excellently controlled during one period (or season), and then have much more
problematic asthma during another. In addition, asthma exacerbations occur in children with both good
and poor short-term asthma control [37–40]. Exacerbations, an important component of asthma control
(table 1), are not covered in the ACT, C-ACT and ACQ. This may explain why the agreement between
asthma control as assessed by ACT or ACQ, as compared to an assessment using BTS or GINA guidelines,
is poor [19, 41]. Specifically, ACT scores appear to underestimate the level of asthma control, as defined
by GINA [41].
All task force members assess asthma control during an interview, which may be supplemented by a
composite asthma control score to help practitioners cover the range of symptoms and the impact on QoL.
Future research should focus on the: usefulness of composite asthma control scores in improving asthma
control in primary and secondary care; external validation and reproducibility of cut-off points in different
populations; and comparison of scores with the patient’s perception and doctor’s assessment of asthma
control, and such studies may include lung function and assessment of airway inflammation.
e-health and telemonitoring
A number of studies have examined the impact of guided self-management by mobile phones or
web-based platforms on asthma control. These were summarised in a recent Cochrane meta-analysis of 21
studies in adults and children. In this review, e-health initiatives did not improve patients’ QoL or reduce
exacerbation and hospitalisation rates in children [42]. At present, e-health initiatives are not routinely
used in the clinical care of children with asthma. However, differences in study design, the patients
included and the type and frequency of interventions makes comparisons of studies difficult, and future
studies might focus on specific patient groups who may indeed benefit from specific e-health initiatives.
Exacerbations
Asthma exacerbations requiring urgent medical care, hospitalisation or the use of an oral corticosteroid
course constitute one of the most troublesome aspects of asthma to patients [19], and severe exacerbations
can be life threatening.
Most asthma exacerbations in children are triggered by viral upper respiratory tract infections [37], but
they also occur after exposure to allergens or irritants [43]. The risk of asthma exacerbations is increased
in children with poor adherence to maintenance therapy, poor asthma control and elevated exhaled nitric
oxide levels, although none of these factors reliably predicts future exacerbation risk [44–47].
All task force members, as supported by guidelines, actively review exacerbations in addition to asthma
control at each consultation in terms of severity, frequency and management [2, 3].
Quality of life
A range of paediatric asthma QoL instruments have been developed, encompassing the impact of asthma
on children’s or their parents’ lives. These have been reviewed in detail elsewhere [48]. The instruments
have been validated (internal consistency, reliability and concurrent associations with other disease
outcomes), but all suffer from psychometric or generalisability limitations [48]. Although QoL correlates
with poor asthma control and reduced lung function [49, 50], children with similar degrees of asthma
control or lung function impairment show considerable QoL differences, which is partly explained by
psychological problems, anxiety and depression [51, 52]. There is consensus that QoL instruments in
childhood asthma provide independent additional information on disease status, complementing symptom
scores and lung function, and have been recommended as a potentially useful additional outcome
parameter to assess response to longer term treatment trials [3, 53]. No studies have assessed whether
asthma management based on routine care plus QoL monitoring is superior to routine asthma
management in improving asthma control and reducing exacerbations and limitations in sports and play.
Paediatric asthma QoL questionnaires contain between 15 and 48 items, and take between 8 and 20 min to
complete [48]. If such instruments are to be used in clinical practice, they are usually completed before the
consultation takes place because they are too time-consuming to be part of the routine 10–15 min
follow-up consultation of a child with asthma. Although the instruments are designed to measure the
impact of asthma on daily life of children, they are primarily developed and suitable for research purposes.
It is unknown how asthmatic children and their parents would feel if they were asked to complete the
same QoL questionnaire repeatedly during long-term follow-up. The structured format of QoL
questionnaires may reduce the desired tailor-made approach in exploring the impact of the disease on an
individual child’s life, and should therefore not replace a normal doctor–patient–parent conversation. An
additional limitation is the cost involved in using copyrighted paediatric QoL questionnaires.
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To date, routine monitoring of QoL in children with asthma does not take place. Studies assessing the
usefulness of longitudinal QoL measures as monitoring tools are needed.
Conclusion
In table 4 the monitoring tools used in the research and clinical practice of symptoms, exacerbations and
QoL are summarised. Monitoring asthma in children in clinical practice requires a careful review of the
impact of the disease on children’s daily activities, including sports and play (table 1). In addition, most task
force members review adherence to maintenance therapy and the patients’ (and parents’) views and beliefs
on the goals of treatment and the amount of treatment required to achieve those goals. Composite asthma
control and QoL measures, although potentially useful in research, have limited value in clinical practice. At
present, telemonitoring of children with asthma does not replace face-to-face follow-up and monitoring.
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